Johannes Duell
- Oncology top 2%
- Pathology and Forensic Medicine top 2%
- Hematology top 2%
- Radiology, Nuclear Medicine and Imaging top 5%
- Molecular Biology
- Co-authors
- Hermann EinseleMax S. ToppLeo RascheAndreas RosenwaldKami J. MaddocksGianluca GaïdanoWojciech JurczakGilles Salles
- Topics
- CAR-T cell therapy research (49 papers)Lymphoma Diagnosis and Treatment (35 papers)Monoclonal and Polyclonal Antibodies Research (24 papers)
- Partner nations
- GermanyUnited StatesFrance
In The Last Decade
Johannes Duell
67 papers receiving 1.7k citations
Hit Papers
Peers
Comparison fields: 5 of 64
- Oncology 1.3k
- Pathology and Forensic Medicine 571
- Hematology 507
- Radiology, Nuclear Medicine and Imaging 482
- Molecular Biology 436
Countries citing papers authored by Johannes Duell
This map shows the geographic impact of Johannes Duell's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Johannes Duell with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Johannes Duell more than expected).
Fields of papers citing papers by Johannes Duell
This network shows the impact of papers produced by Johannes Duell. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Johannes Duell. The network helps show where Johannes Duell may publish in the future.
Co-authorship network of co-authors of Johannes Duell
This figure shows the co-authorship network connecting the top 25 collaborators of Johannes Duell. A scholar is included among the top collaborators of Johannes Duell based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Johannes Duell. Johannes Duell is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 1 | |
| 2 | 0 | |
| 3 | 0 | |
| 4 | 1 | |
| 5 | 4 | |
| 6 | 1 | |
| 7 | 5 | |
| 8 | 25 | |
| 9 | 12 | |
| 10 | 1 | |
| 11 | 1 | |
| 12 | 16 | |
| 13 | 43 | |
| 14 | 5 | |
| 15 | 28 | |
| 16 | Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 studybreakdown → | 324 |
| 17 | 63 | |
| 18 | 110 | |
| 19 | 55 | |
| 20 | 71 |
About Johannes Duell
Johannes Duell is a scholar working on Oncology, Pathology and Forensic Medicine and Genetics, having authored 72 papers that have together received 1.7k indexed citations. Recurring topics across this work include CAR-T cell therapy research (49 papers), Lymphoma Diagnosis and Treatment (35 papers) and Monoclonal and Polyclonal Antibodies Research (24 papers). The work is most often cited by research in Oncology (1.3k citations), Hematology (507 citations) and Pathology and Forensic Medicine (571 citations). Johannes Duell has collaborated with scholars based in Germany, United States and France. Frequent co-authors include Hermann Einsele, Max S. Topp, Leo Rasche, Andreas Rosenwald, Max S. Topp, Kami J. Maddocks, Gianluca Gaïdano, Wojciech Jurczak, Gilles Salles and Aleš Obr. Their work appears in journals such as Journal of Clinical Oncology, Blood and PLoS ONE.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.